GSK wins FDA label expansion for RSV vaccine, Arexvy
Source: SeekingAlpha
2026-03-13 07:12:33 ET
More on GSK, Agenus
- GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
- GSK plc 2025 Q4 - Results - Earnings Call Presentation
- GSK gains approval of leucovorin for rare genetic disorder
- Agenus receives $20M payment under Zydus Life Sciences collaboration
Read the full article on Seeking Alpha
For further details see:
GSK wins FDA label expansion for RSV vaccine, Arexvy
GlaxoSmithKline PLC
NASDAQ: GSK
GSK Trading
-0.44% G/L:
$51.91 Last:
2,379,187 Volume:
$52.17 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
